1. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479
2. Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res: Off J Am Assoc Cancer Res 7:839–845
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D, Perry A, Reifenberger G, von Deimling A (2016) WHO classification of tumours of the central nervous system, 4th edn. International agency for research on cancer, Lyon
4. WHO Classification of Tumours Editorial Board (2021) Central nervous system tumours, 5th edn. International Agency for Research on Cancer, Lyon
5. Franceschi E, Tosoni A, Bartolini S et al (2020) Histopathological grading affects survival in patients with IDH-mutant grade II and grade III diffuse gliomas. Eur J Cancer 137:10–17